Efficacy of macrolides used in combination with ethambutol, with or without other drugs, against Mycobacterium avium within human macrophages

International Journal of Antimicrobial Agents

Volumn 18, Issue 6, 2001, Pages 525-530

  Schiavano, Giuditta F ^a   Celeste, Angela G ^a   Salvaggio, Leonardo ^b   Sisti, Maurizio ^a   Brandi, Giorgio ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antimicrobial drugs; Intracellular killing; Macrophages; Mycobacterium avium

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; MACROLIDE; RIFAMPICIN; ROXITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRACELLULAR KILLING; MACROPHAGE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CELLS, CULTURED; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; RIFAMPIN;

EID: 0035216064     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00461-7     Document Type: Article

References (36)

1. Mycobacterium avium complex infection in the acquired immune deficiency syndrome
2. Mycobacterium avium complex infection and AIDS: Advances in theory and practice
3. Incidence of Mycobacterium avium-intracellulare complex bacteremia in HIV-positive patients
4. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
5. A randomised comparison of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy
6. Treatment of Mycobacterium avium in human immunodeficiency virus-fected individuals
7. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin
8. Clarithromycin: A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome
9. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomised, double-blind, dose-ranging study in patient with AIDS
10. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial
11. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus
12. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex
13. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages
14. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice
15. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope
16. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis
17. Combination of rifampin or rifabutin plus Ethambutol against Mycobacterium avium complex
18. EMB: Mode of action, biotransformation and pharmacokinetics
19. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis
20. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection
21. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection
22. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages
23. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium
24. A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals
25. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex
26. In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex
27. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic
28. Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium
29. The phagosome environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin
30. Uptake of antibiotics by human alveolar macrophages
31. Accumulation of clarythromycin in macrophages infected with Mycobacterium avium
32. Therapy of mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes
33. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection
34. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. Intracellulare complex infection
35. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies
36. Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection